|
Indicator: 1
[Output]
Measurements in/of Recommendations Made
Relationships: Department of Health and Human Services - Narrower_Than
Other Information:
Advisory Committee on Blood Safety and Availability
| Type |
Target |
Actual |
| StartDate |
2010-10-01 |
2010-10-01 |
| EndDate |
2011-09-30 |
2011-09-30 |
| Number |
n/a |
17 |
| Description |
Unspecified |
At the November 2010 meeting 4 recommendations for Blood Safety, Cell/Tissue, Organ and Cross-Cutting that identified priorites
in these areas. During the two day meeting, a number of experts in the field presented information that fostered a vigorous
debate among Committee members and public members of the audience. After careful consideration of the collective input, the
Committee developed the following outline of key strategic priorities for blood, tissues, and organs safety, including cross-cutting
priorities:Blood Safety Priorities: Patient Safety - Promote and establish high value and effective evidence-based patient
blood managementProduct Safety - Fund safety technology development and implementation (e.g., pathogen reduction technology
and infectious disease/emerging infectious disease testing) - Establish an evidence-based donor history questionnaire - Fully
reimburse costs of safety measures Biovigilance - Fully establish Biovigilance for blood donors and recipients to improve
outcomes Donor Wellness - Promote and protect donor health Risk Management - Improve risk-based decision making and communication
(e.g., informed consent) Cell/Tissue Priorities: Product Safety - Determine the elements that contribute to product safety
- Assess the intrinsic quality of cell and tissue products - Determine the optimal processing and testing of cells/tissues
to mitigate disease transmission - Establish an evidence-based donor history questionnairePatient Safety / Risk Management
- Improve risk-based decision making and communication for optimal tissue utilization (e.g., informed consent)Biovigilance
- Establish Biovigilance for cell and tissue recipients to improve communication, traceability, and outcomesOrgans Priorities:Product
Safety - Support the development of technologies for appropriate rapid screening of transmissible markers to quality organ
availability- Establish evidence-based donor history questionnairePatient Safety / Risk Management - Improve risk-based decision
making and communication for optimal patient management (e.g., informed consent)Biovigilance - Establish Biovigilance for
organ recipients to improve communication, traceability, and outcomesCross-cutting Priorities: - Improve flexible funding
mechanisms for emerging public health priorities- Increase public awareness of issues affecting the safety and availability
of blood, cells, tissues, and organs- Support International Collaborations that additionally leverage international experienceThe
Committee feels that adoption of its strategic outline for blood, organs, and tissues safety, including cross-cutting priorities,
will place the Department on firm footing for strategic planning in the area of public policy for transfusion and transplantation
safety. It is the Committee’s genuine desire to continue working with the Department in guiding and recommending the best
path forward in the development of its strategic plans and initiativesDuring the two day June 2011 ACBSA Meeting, a number
of experts in the field presented information that fostered a vigorous debate among Committee members and public members of
the audience. After careful consideration of the collective input, the Committee developed the following outline of key strategic
priorities for blood, tissues, and organs safety, including cross-cutting priorities:Blood Safety Priorities: Patient Safety
- Promote and establish high value and effective evidence-based patient blood managementProduct Safety - Fund safety technology
development and implementation (e.g., pathogen reduction technology and infectious disease/emerging infectious disease testing)
- Establish an evidence-based donor history questionnaire - Fully reimburse costs of safety measures Biovigilance - Fully
establish Biovigilance for blood donors and recipients to improve outcomes Donor Wellness - Promote and protect donor health
Risk Management - Improve risk-based decision making and communication (e.g., informed consent) Cell/Tissue Priorities: Product
Safety - Determine the elements that contribute to product safety - Assess the intrinsic quality of cell and tissue products
- Determine the optimal processing and testing of cells/tissues to mitigate disease transmission - Establish an evidence-based
donor history questionnairePatient Safety / Risk Management - Improve risk-based decision making and communication for optimal
tissue utilization (e.g., informed consent)Biovigilance - Establish Biovigilance for cell and tissue recipients to improve
communication, traceability, and outcomesOrgans Priorities:Product Safety - Support the development of technologies for appropriate
rapid screening of transmissible markers to quality organ availability- Establish evidence-based donor history questionnairePatient
Safety / Risk Management - Improve risk-based decision making and communication for optimal patient management (e.g., informed
consent)Biovigilance - Establish Biovigilance for organ recipients to improve communication, traceability, and outcomesCross-cutting
Priorities: - Improve flexible funding mechanisms for emerging public health priorities- Increase public awareness of issues
affecting the safety and availability of blood, cells, tissues, and organsPage 3 – Dr. Koh- Support International Collaborations
that additionally leverage international experienceThe Committee feels that adoption of its strategic outline for blood, organs,
and tissues safety, including cross-cutting priorities, will place the Department on firm footing for strategic planning in
the area of public policy for transfusion and transplantation safety. It is the Committee’s genuine desire to continue working
with the Department in guiding and recommending the best path forward in the development of its strategic plans and initiatives
|
|
